SK Biopharmaceuticals and Eurofarma Form Joint Venture to Transform Epilepsy Treatment

SK Biopharmaceuticals Forms Joint Venture to Revolutionize Epilepsy Management

SK Biopharmaceuticals, a frontrunner in the field of biotechnology focusing on central nervous system disorders and oncology, announces the establishment of a joint venture named Mentis Care, Inc. This strategic collaboration with Brazilian pharmaceutical company Eurofarma marks a pivotal expansion into digital healthcare. The launch event, held on October 20, 2025, in Toronto, Canada, signifies a commitment to enhancing patient care through innovative technology. With Eurofarma's extensive reach in 24 countries across North America, Latin America, and Africa, the partnership aims to leverage combined expertise to address pressing healthcare challenges in epilepsy management.

Mentis Care is set to develop an AI-driven epilepsy management platform that integrates advanced technologies like AI-powered electroencephalography (EEG) and wearable devices for real-time seizure detection. Since 2018, SK Biopharmaceuticals has been refining these technologies to create solutions that not only monitor seizures but also provide clinical decision support tools for healthcare providers. This comprehensive digital platform is designed to offer personalized patient care, making it a significant advancement in the management of epilepsy. By harnessing real-time data, Mentis Care aims to empower both patients and healthcare professionals with actionable insights, ultimately striving to improve patient outcomes.

Situated in the MaRS Discovery District, a renowned innovation hub in Toronto, Mentis Care plans to bolster its workforce and cultivate partnerships with academic institutions and industry leaders. This strategic location not only supports collaboration but also provides a fertile ground for clinical validation of their AI algorithms. The joint venture represents a bold step for SK Biopharmaceuticals, reflecting its vision to revolutionize epilepsy care through cutting-edge technology and collaborative efforts in a rapidly evolving healthcare landscape.

In addition to its technological innovations, Mentis Care emphasizes the importance of integrating real-time data analytics with patient care strategies. The goal is to create a seamless connection between patients' day-to-day experiences and clinical interventions, ultimately leading to more effective management of epilepsy. The collaboration with Eurofarma is expected to enhance the reach of these innovations, ensuring that more patients benefit from advanced care solutions.

As SK Biopharmaceuticals embarks on this new venture, the focus remains on improving healthcare delivery through technology. The joint effort reflects a broader trend in the pharmaceutical and biotech industries, where companies are increasingly recognizing the potential of digital solutions in enhancing patient care and outcomes.